KRAS Mutations Predict Shorter Survival in Lung Cancer

This article originally appeared here.
<i>KRAS</i> Mutations Predict Shorter Survival in Lung Cancer
KRAS Mutations Predict Shorter Survival in Lung Cancer

THURSDAY, July 26 (HealthDay News) -- For patients with advanced lung adenocarcinomas, KRAS mutations predict shorter survival, according to a study published online July 18 in Cancer.

Melissa L. Johnson, M.D., from Northwestern University in Chicago, and colleagues examined the prognostic significance of KRAS mutations using data from 1,036 patients (59 percent women; 33 percent never-smokers) with advanced lung adenocarcinomas with known EGFR and KRAS status, who were evaluated between 2002 and 2009.

The researchers found that the patients had a median age of 65 years, and 81 percent had a Karnofsky performance status of 80 percent or greater. EGFR mutations correlated with longer overall survival (hazard ratio, 0.60; P < 0.001) and KRAS mutations with shorter survival (hazard ratio, 1.21; P = 0.048), in multivariate analysis.

"In conclusion, we report here that the presence of a KRAS mutation is a poor prognostic factor for patients with lung adenocarcinomas," the authors write. "Because patients with KRAS mutations have a distinct clinical course that results in shorter survival, they should be evaluated separately in clinical trials. We recommend including KRAS testing in upfront mutation analyses along with testing for EGFR mutations and EML4-ALK to prospectively identify these patients in the clinic."

Several authors disclosed financial ties to pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs